This article has been updated to reflect further commentary made by the company.

NEW YORK (GenomeWeb) – Last month, iCareDx announced that it was rebranding itself as Acuamark Diagnostics as it works to raise funds for its first round of clinical testing.

"It is a more precise reflection of what we are doing," Acuamark President and CEO Bernard Peperstraete told GenomeWeb. "Acua is also a play on accurate and liquid, and Acuamark — or watermark — reflects that each cancer leaves a barely visible imprint, and needs to be looked at in a different light."

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.